New drug cocktail shows promise for tough liver cancer
NCT ID NCT02519348
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested different combinations of immune-boosting drugs (durvalumab, tremelimumab, and bevacizumab) in 433 adults with advanced liver cancer that had worsened after standard treatment. The goal was to see if these drugs are safe and can shrink tumors or slow the disease. While not a cure, the approach aims to give patients more time and better control over their cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Phoenix, Arizona, 85054, United States
-
Research Site
San Francisco, California, 94158, United States
-
Research Site
New Haven, Connecticut, 06510, United States
-
Research Site
Jacksonville, Florida, 32224, United States
-
Research Site
Tampa, Florida, 33612, United States
-
Research Site
Indianapolis, Indiana, 46202, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Stony Brook, New York, 11794, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Portland, Oregon, 97213, United States
-
Research Site
Philadelphia, Pennsylvania, 19107, United States
-
Research Site
Philadelphia, Pennsylvania, 19111, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Dallas, Texas, 75390, United States
-
Research Site
Seattle, Washington, 98109, United States
-
Research Site
Hangzhou, 310016, China
-
Research Site
Nanjing, 210002, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Hong Kong, Hong Kong
-
Research Site
Shatin, Hong Kong
-
Research Site
Benevento, 82100, Italy
-
Research Site
Milan, 20133, Italy
-
Research Site
Roma, 00168, Italy
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Kashiwa, 277-8577, Japan
-
Research Site
Osakasayama-shi, 589-8511, Japan
-
Research Site
Bukit Merah, 169610, Singapore
-
Research Site
Singapore, 119074, Singapore
-
Research Site
Singapore, 308433, Singapore
-
Research Site
Busan, 49241, South Korea
-
Research Site
Junggu, 41944, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06273, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Barcelona, 08036, Spain
-
Research Site
Córdoba, 14004, Spain
-
Research Site
Pamplona, 31008, Spain
-
Research Site
Kaohsiung City, 83301, Taiwan
-
Research Site
Taipei, 100, Taiwan
-
Research Site
Taoyuan City, 333, Taiwan